Aurobindo Pharma Ltd
NSE:AUROPHARMA

Watchlist Manager
Aurobindo Pharma Ltd Logo
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Watchlist
Price: 1 262.45 INR 0.65%
Market Cap: 733.2B INR
Have any thoughts about
Aurobindo Pharma Ltd?
Write Note

Aurobindo Pharma Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aurobindo Pharma Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Cost of Revenue
-â‚ą125.2B
CAGR 3-Years
-8%
CAGR 5-Years
-7%
CAGR 10-Years
-12%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Cost of Revenue
-â‚ą88.2B
CAGR 3-Years
-8%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Cost of Revenue
-â‚ą87.5B
CAGR 3-Years
-3%
CAGR 5-Years
-9%
CAGR 10-Years
-8%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Cost of Revenue
-â‚ą104.9B
CAGR 3-Years
-2%
CAGR 5-Years
-4%
CAGR 10-Years
-8%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Cost of Revenue
-â‚ą27.5B
CAGR 3-Years
-7%
CAGR 5-Years
-4%
CAGR 10-Years
-8%
M
Mankind Pharma Ltd
NSE:MANKIND
Cost of Revenue
-â‚ą34B
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Aurobindo Pharma Ltd
Glance View

Market Cap
739.7B INR
Industry
Pharmaceuticals

Aurobindo Pharma Ltd., founded in 1986 by P.V. Ramprasad Reddy and K. Nityananda Reddy, began its journey in the bustling pharmaceutical landscape of Hyderabad, India. Initially starting as a provider of semi-synthetic penicillin, the company gradually diversified its product portfolio across major therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, and anti-diabetics, among others. With an entrepreneurial vision, Aurobindo leveraged vertical integration to optimize costs and operations—manufacturing everything from raw active pharmaceutical ingredients (APIs) to finished dosage formulations. This strategic approach not only reinforced its cost-leadership position but also enabled the company to meet stringent regulatory requirements in global markets, providing them a competitive edge. In its quest for expansion, Aurobindo penetrated international markets, including the United States and Europe, through acquisitions and strategic alliances, expanding its manufacturing capabilities and distribution networks. The company generates its revenue primarily through the sale of generic pharmaceuticals, which are manufactured in their state-of-the-art facilities and sold worldwide. Aurobindo's robust research and development (R&D) investments have further fueled its growth by enabling the company to introduce new and complex product lines, including biosimilars and specialty generics. This blend of strategic foresight, operational excellence, and commitment to innovation is what propels Aurobindo Pharma's ongoing narrative in the global pharmaceutical industry.

AUROPHARMA Intrinsic Value
1 134.89 INR
Overvaluation 10%
Intrinsic Value
Price

See Also

What is Aurobindo Pharma Ltd's Cost of Revenue?
Cost of Revenue
-125.2B INR

Based on the financial report for Jun 30, 2024, Aurobindo Pharma Ltd's Cost of Revenue amounts to -125.2B INR.

What is Aurobindo Pharma Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-12%

Over the last year, the Cost of Revenue growth was -8%. The average annual Cost of Revenue growth rates for Aurobindo Pharma Ltd have been -8% over the past three years , -7% over the past five years , and -12% over the past ten years .

Back to Top